Table 4.
Toxicity from Phase II studies with trabectedin single agent or in combination
| First author | Dose, schedule | Neutropenia (%) | Thrombocytopenia (%) | Elevation of AST (%) | Elevation of ALT (%) | Fatigue (%) |
|---|---|---|---|---|---|---|
| Sessa (2005)56 | 1.3 mg/m2, q21-d | 41 | 7 | 75a | – | 7 |
| Krasner (2007)57 | 0.58 mg/m2, (infusion 3-h), weekly for 3 weeks, q28-d | 8 | 3 | 3 | 12 | 5 |
| Del Campo (2009)58 | 1.5 mg/m2 (infusion 24-h), q21-d versus 1.3 mg/m2 (infusion 3-h), q21-d | 54 38 |
8 10 |
35 19 |
56 58 |
15 8 |
Note:
a
From grouped data about AST and ALT.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; h, hours; q, every.